How close are we to individualized medicine for Parkinson’s disease?

References

• Nussbaum R, Ellis C. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348(14):1356–1364.
   PubMed Web of Science ®Google Scholar
• Kempster PA, O’Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(Pt 6):1755–1762.
   PubMed Web of Science ®Google Scholar
• Wickremaratchi M, Knipe M, Sastry B, et al. The motor phenotype of Parkinson’s disease in relation to age at onset. Mov Disord. 2011;26(3):457–463.
   PubMed Web of Science ®Google Scholar
• Sweet RD. Five years’ treatment of Parkinson’s disease with levodopa. Ann Intern Med. 1975;83(4):456.
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–2508.
   PubMed Web of Science ®Google Scholar
• Fahn S, Jankovic S, Hallett M. Principles and practice of movement disorders. 2nd ed. Philadelphia (PA): Saunders Elsevier; 2011.
   Google Scholar
• Gerretsen P, Pollock BG. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin Drug Metab Toxicol. 2008;4(12):1465–1478.
   PubMed Web of Science ®Google Scholar
• Personalized Medicine 101. [cited 2015 Dec 1]. Available from: http://www.personalizedmedicinecoalition.org/Education/Overview#sthash.Q7tEHNz4.dpuf
   Google Scholar
• Moreau C, Meguig S, Corvol JC, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain. 2015;138(Pt 5):1271–1283.
   PubMed Web of Science ®Google Scholar
• Kalinderi K, Fidani L, Katsarou Z, et al. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson’s disease. Int J Clin Pract. 2011;65(12):1289–1294.
   PubMed Web of Science ®Google Scholar
• Tai CH, Wu RM. Catechol-O-methvltransferase and Parkinson’s disease. Acta Med Okayama. 2002;56(1):1–6.
   PubMed Web of Science ®Google Scholar
• Winqvist R, Lundström K, Salminen M, et al. The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenet Cell Genet. 1992;59(4):253–257.
   PubMedGoogle Scholar
• Hernán M, Checkoway H, O’Brien R, et al. MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology. 2002;58(9):1381–1387.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim J-Y, Kim J-M, et al. No correlation between COMT genotype and entacapone benefits in Parkinson’s disease. Neurology Asia. 2011;16(3):211–216.
   Web of Science ®Google Scholar
• Watanabe M, Harada S, Nakamura T, et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson’s disease. Neuropsychobiology. 2003;48(4):190–193.
   PubMed Web of Science ®Google Scholar
• Lee MS, Kim HS, Cho EK, et al. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson’s disease. Neurology. 2002;58(4):564–567.
   PubMed Web of Science ®Google Scholar
• Lachman H, Papolos D, Saito T, et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243–250.
   PubMedGoogle Scholar
• Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34(13):4202–4210.
   PubMed Web of Science ®Google Scholar
• Bialecka M, Kurzawski M, Klodowska-Duda G, et al. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson’s disease, levodopa treatment response, and complications. Pharmacogenet Genomics. 2008;18(9):815–821.
   PubMed Web of Science ®Google Scholar
• Contin M, Martinelli P, Mochi M, et al. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson’s disease. Mov Disord. 2005;20(6):734–739.
   PubMed Web of Science ®Google Scholar
• Wu H, Dong F, Wang Y, et al. Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(10):1094–1096.
   PubMed Web of Science ®Google Scholar
• Lee MS, Lyoo CH, Ulmanen I, et al. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson’s disease. Neurosci Lett. 2001;298(2):131–134.
   PubMed Web of Science ®Google Scholar
• Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson’s disease: a randomized crossover clinical trial. Ann Neurol. 2011;69(1):111–118.
   PubMed Web of Science ®Google Scholar
• Chong DJ, Suchowersky O, Szumlanski C, et al. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson’s disease. Clin Neuropharmacol. 2000;12(3):143–148.
   Web of Science ®Google Scholar
• Torkaman-Boutorabi A, Shahidi GA, Choopani S, et al. Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson’s disease in an Iranian population. Folia Neuropathologica. 2012;4:382–389.
   Web of Science ®Google Scholar
• Hsu Y, Powell J, Sims K, et al. Molecular genetics of the monoamine oxidases. J Neurochem. 1989;53(1):12–18.
   PubMed Web of Science ®Google Scholar
• Murphy D, Wright C, Buchsbaum M, et al. Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med. 1976;16(3):254–265.
   Web of Science ®Google Scholar
• Balciuniene J, Emilsson L, Oreland L, et al. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet. 2002;110(1):1–7.
   PubMed Web of Science ®Google Scholar
• Hao H, Shao M, An J, et al. Association of catechol-O-methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson’s disease in a Chinese population. Parkinsonism Relat Disord. 2014;20(10):1041–1045.
   PubMed Web of Science ®Google Scholar
• Garpenstrand H, Ekblom J, Forslund K, et al. Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J Neural Transm (Vienna). 2000;107(5):523–530.
   PubMed Web of Science ®Google Scholar
• Costa-Mallen P, Kelada SN, Costa LG, et al. Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene. Neurosci Lett. 2005;383(1–2):171–175.
   PubMed Web of Science ®Google Scholar
• Pivac N, Knezevic J, Mustapic M, et al. The lack of association between monoamine oxidase (MAO) intron 13 polymorphism and platelet MAO-B activity among men. Life Sci. 2006;79(1):45–49.
   PubMed Web of Science ®Google Scholar
• Winblad B, Gottfries C, Oreland L, et al. Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients. Med Biol. 1979;57(2):129–132.
   PubMedGoogle Scholar
• Young WJ, Laws EJ, Sharbrough F, et al. Human monoamine oxidase. Lack of brain and platelet correlation. Arch Gen Psychiatry. 1986;43(6):604–609.
   PubMed Web of Science ®Google Scholar
• Ekblom J, Garpenstrand H, Damberg M, et al. Transcription factor binding to the core promoter of the human monoamine oxidase B gene in the cerebral cortex and in blood cells. Neurosci Lett. 1998;258(2):101–104.
   PubMed Web of Science ®Google Scholar
• Bialecka M, Drozdzik M, Klodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson’s disease. Acta Neurol Scand. 2004;110(4):260–266.
   PubMed Web of Science ®Google Scholar
• Torkaman-Boutorabi A, Shahidi GA, Choopani S, et al. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson’s disease. Acta Neurobiol Exp (Wars). 2012;72(3):272–282.
   PubMed Web of Science ®Google Scholar
• Flegontova OV, Khrunin AV, Lylova OI, et al. Haplotype frequencies at the DRD2 locus in populations of the East European plain. BMC Genet. 2009;10:62.
   PubMed Web of Science ®Google Scholar
• Jönsson E, Nöthen M, Grünhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999;4(3):290–296.
   PubMed Web of Science ®Google Scholar
• Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics. 1997;7(6):479–484.
   PubMedGoogle Scholar
• Paus S, Grunewald A, Klein C, et al. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson’s disease. Mov Disord. 2008;23(4):599–602.
   PubMed Web of Science ®Google Scholar
• Liu YZ, Tang BS, Yan XX, et al. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson’s disease patients. Eur J Clin Pharmacol. 2009;65(7):679–683.
   PubMed Web of Science ®Google Scholar
• Zhang F, Fan H, Xu Y, et al. Converging evidence implicates the dopamine D3 receptor gene in vulnerability to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(5):613–619.
   PubMed Web of Science ®Google Scholar
• Lundstrom K, Turpin M. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun. 1996;225(3):1068–1072.
   PubMed Web of Science ®Google Scholar
• Jeanneteau F, Funalot B, Jankovic J, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006;103(28):10753–10758.
   PubMed Web of Science ®Google Scholar
• Vallelunga A, Flaibani R, Formento-Dojot P, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2012;18(4):397–399.
   PubMed Web of Science ®Google Scholar
• Gainetdinov R, Jones S, Fumagalli F, et al. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev. 1998;26(2–3):148–153.
   PubMedGoogle Scholar
• Vandenbergh D, Persico A, Hawkins A, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992;14(4):1104–1106.
   PubMed Web of Science ®Google Scholar
• van Dyck C, Malison R, Jacobsen L, et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med. 2005;46(5):745–751.
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Staley J, Zoghbi S, et al. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry. 2000;157(10):1700–1703.
   PubMed Web of Science ®Google Scholar
• Fuke S, Suo S, Takahashi N, et al. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001;1(2):152–156.
   PubMedGoogle Scholar
• VanNess SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 2005;6:55.
   PubMed Web of Science ®Google Scholar
• Dreher JC, Kohn P, Kolachana B, et al. Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci U S A. 2009;106(2):617–622.
   PubMed Web of Science ®Google Scholar
• Forbes EE, Brown SM, Kimak M, et al. Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry. 2009;14(1):60–70.
   PubMed Web of Science ®Google Scholar
• Martinez D, Gelernter J, Abi-Dargham A, et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology. 2001;24(5):553–560.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Mozley PD, Sokol S, et al. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson’s disease. Mov Disord. 2003;18(7):804–812.
   PubMed Web of Science ®Google Scholar
• Schumacher-Schuh AF, Francisconi C, Altmann V, et al. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson’s disease. Int J Neuropsychopharmacol. 2013;16:1251–1258.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):S11–S16.
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379–1389.
   PubMed Web of Science ®Google Scholar
• Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62(4):601–605.
   PubMed Web of Science ®Google Scholar
• Grandas F, Galiano M, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson’s disease. J Neurol. 1999;246(12):1127–1133.
   PubMed Web of Science ®Google Scholar
• Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011;69(6):919–927.
   PubMed Web of Science ®Google Scholar
• Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord. 2005;20(8):919–931.
   PubMed Web of Science ®Google Scholar
• Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease. J Clin Neurosci. 2012;19(3):343–348.
   PubMed Web of Science ®Google Scholar
• Rylander D, Parent M, O’Sullivan SS, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol. 2010;68(5):619–628.
   PubMed Web of Science ®Google Scholar
• Oliveri R, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology. 1999;53(7):1425–1430.
   PubMed Web of Science ®Google Scholar
• Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2006;21(5):654–659.
   PubMed Web of Science ®Google Scholar
• Kaplan N, Vituri A, Korczyn A, et al. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson’s disease. J Mol Neurosci. 2014;53(2):183–188.
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho J, Lee EK, et al. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease. Mov Disord. 2011;26(1):73–79.
   PubMed Web of Science ®Google Scholar
• Kaiser R, Hofer A, Grapengiesser A, et al. L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology. 2003;60(11):1750–1755.
   PubMed Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics. 2012;13(15):1701–1710.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu Z, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology. 2001;56(12):1757–1759.
   PubMed Web of Science ®Google Scholar
• Paus S, Gadow F, Knapp M, et al. Motor complications in patients form the German competence network on Parkinson’s disease and the DRD3 Ser9Gly polymorphism. Mov Disord. 2009;24(7):1080–1084.
   PubMed Web of Science ®Google Scholar
• Cheshire P, Bertram K, Ling H, et al. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson’s disease. Neurodegener Dis. 2014;13(1):24–28.
   PubMed Web of Science ®Google Scholar
• de Lau LM, Verbaan D, Marinus J, et al. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord. 2012;27(1):132–135.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Farrer MJ, Stone JT, et al. Phenotypic associations of tau and APOE in Parkinson’s disease. Neurosci Lett. 2007;414(2):141–144.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Yueh KC, Lin SZ, et al. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson’s disease. J Neurol Sci. 2007;252(2):130–134.
   PubMed Web of Science ®Google Scholar
• Pascale E, Purcaro C, Passarelli E, et al. Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson’s disease and of L-dopa-induced adverse effects. J Neurol Sci. 2009;276(1–2):18–21.
   PubMed Web of Science ®Google Scholar
• Foltynie T, Cheeran B, Williams-Gray CH, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(2):141–144.
   PubMed Web of Science ®Google Scholar
• Gao L, Diaz-Corrales FJ, Carrillo F, et al. Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson’s disease. Acta Neurol Scand. 2010;122(1):41–45.
   PubMed Web of Science ®Google Scholar
• Svetel M, Pekmezovic T, Markovic V, et al. No association between brain-derived neurotrophic factor G196A polymorphism and clinical features of Parkinson’s disease. Eur Neurol. 2013;70(5–6):257–262.
   PubMed Web of Science ®Google Scholar
• Molchadski I, Korczyn A, Cohen O, et al. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta Neurol Scand. 2011;123(2):117–121.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu Z, Chen B. Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Neurosci Lett. 2001;308(1):21–24.
   PubMed Web of Science ®Google Scholar
• Baydyuk M, Russell T, Liao GY, et al. TrkB receptor controls striatal formation by regulating the number of newborn striatal neurons. Proc Natl Acad Sci U S A. 2011;108(4):1669–1674.
   PubMed Web of Science ®Google Scholar
• Hyman C, Hofer M, Barde Y, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991;350(6315):230–232.
   PubMed Web of Science ®Google Scholar
• van der Kolk NM, Speelman AD, van Nimwegen M, et al. BDNF polymorphism associates with decline in set shifting in Parkinson’s disease. Neurobiol Aging. 2015;36(3):1605 e1–e6.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson’s disease. Neurodegener Dis. 2013;11(2):63–71.
   PubMed Web of Science ®Google Scholar
• Bares CB, Delva J, Grogan-Kaylor A, et al. Family and parenting characteristics associated with marijuana use by Chilean adolescents. Subst Abuse Rehabil. 2011;2011(2):1–11.
   PubMedGoogle Scholar
• Weintraub D, Papay K, Siderowf A; Parkinson’s Progression Markers Initiative. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013;80(2):176–180.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza M, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–844.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim JM, Kim JW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord. 2010;16(3):202–207.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14(1):28–32.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf A, Potenza M, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969–973.
   PubMedGoogle Scholar
• Voon V, Thomsen T, Miyasaki J, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64(2):212–216.
   PubMedGoogle Scholar
• Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67(7):1254–47.
   PubMed Web of Science ®Google Scholar
• Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(3):411–415.
   PubMed Web of Science ®Google Scholar
• Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):121–127.
   PubMed Web of Science ®Google Scholar
• Voon V, Potenza M, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson’s disease. Curr Opin Neurol. 2007;20(4):484–492.
   PubMed Web of Science ®Google Scholar
• Napier TC, Corvol JC, Grace AA, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):141–149.
   PubMed Web of Science ®Google Scholar
• Bezdjian S, Baker LA, Tuvblad C. Genetic and environmental influences on impulsivity: a meta-analysis of twin, family and adoption studies. Clin Psychol Rev. 2011;31(7):1209–1223.
   PubMed Web of Science ®Google Scholar
• Kim YE, Jeon BS. Genetic susceptibility of impulse control and related behavior in Parkinson’s disease. J Parkinsons Dis. 2014;4(2):261–272.
   PubMedGoogle Scholar
• Le Foll B, Gallo A, Le Strat Y, et al. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol. 2009;20(1):1–17.
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Giros B, Martres M, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347(6289):146–151.
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord. 2009;24(12):1803–1810.
   PubMed Web of Science ®Google Scholar
• Lee J-Y, Jeon BS, Kim H-J, et al. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(1):76–78.
   PubMed Web of Science ®Google Scholar
• Zainal Abidin S, Tan EL, Chan SC, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson’s disease patients. BMC Neurol. 2015;15:59.
   PubMed Web of Science ®Google Scholar
• Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson’s disease. Exp Neurol. 2013;243:45–56.
   PubMed Web of Science ®Google Scholar
• Frucht S, Rogers J, Greene P, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–1910.
   PubMed Web of Science ®Google Scholar
• Paus S, Seeger G, Brecht HM, et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson’s disease. Mov Disord. 2004;19(6):705–707.
   PubMed Web of Science ®Google Scholar
• Korner Y, Meindorfner C, Moller JC, et al. Predictors of sudden onset of sleep in Parkinson’s disease. Mov Disord. 2004;19(11):1298–1305.
   PubMed Web of Science ®Google Scholar
• Manni R, Terzaghi M, Sartori I, et al. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. Sleep Med. 2004;5(2):189–193.
   PubMed Web of Science ®Google Scholar
• Montastruc J, Brefel-Courbon C, Senard J, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol. 2001;24(3):181–183.
   PubMed Web of Science ®Google Scholar
• Rissling I, Geller F, Bandmann O, et al. Dopamine receptor gene polymorphisms in Parkinson’s disease patients reporting “sleep attacks”. Mov Disord. 2004;19(11):1279–1284.
   PubMed Web of Science ®Google Scholar
• Frauscher B, Högl B, Maret S, et al. Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. Sleep. 2004;27(4):733–736.
   PubMed Web of Science ®Google Scholar
• Rissling I, Frauscher B, Kronenberg F, et al. Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. Sleep. 2006;29(1):108–111.
   PubMed Web of Science ®Google Scholar
• Rissling I, Körner Y, Geller F, et al. Preprohypocretin polymorphisms in Parkinson disease patients reporting “sleep attacks”. Sleep. 2005;28:871–875.
   PubMed Web of Science ®Google Scholar
• Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson’s disease: many causes, few therapeutic options. J Neurol Sci. 2012;314(1–2):12–19.
   PubMed Web of Science ®Google Scholar
• Factor SA, Steenland NK, Higgins DS, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson’s disease. Mov Disord. 2011;26(12):2190–2195.
   PubMed Web of Science ®Google Scholar
• Goldman J, Goetz C, Berry-Kravis E, et al. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004;61(8):1280–1284.
   PubMedGoogle Scholar
• Goetz C, Burke P, Leurgans S, et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001;58(2):209–213.
   PubMedGoogle Scholar
• Makoff A, Graham J, Arranz M, et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics. 2000;10(1):43–48.
   PubMedGoogle Scholar
• Wang J, Zhao C, Chen B, et al. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson’s disease. Neurosci Lett. 2004;355(3):193–196.
   PubMed Web of Science ®Google Scholar
• Kiferle L, Ceravolo R, Petrozzi L, et al. Visual hallucinations in Parkinson’s disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett. 2007;422(3):228–231.
   PubMed Web of Science ®Google Scholar
• Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson’s disease: relationship to dementia and hallucinations. Mov Disord. 2005;20(8):989–994.
   PubMed Web of Science ®Google Scholar
• Crawley J, Corwin R. Biological actions of cholecystokinin. Peptides. 1994;15(4):731–755.
   PubMed Web of Science ®Google Scholar
• Wang J, Si YM, Liu Z, et al. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson’s disease. Pharmacogenetics. 2003;13(6):365–369.
   PubMedGoogle Scholar
• Fujii C, Harada S, Ohkoshi N, et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson’s disease. Clin Genet. 1999;56(5):394–399.
   PubMed Web of Science ®Google Scholar
• Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand. 2006;113(1):14–17.
   PubMed Web of Science ®Google Scholar
• de la Fuente-Fernández R, Núñez M, López E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson’s disease. Clin Neuropharmacol. 1999;22(4):226–230.
   PubMed Web of Science ®Google Scholar
• Pavlova R, Mehrabian S, Petrova M, et al. Cognitive, neuropsychiatric, and motor features associated with apolipoprotein E epsilon4 allele in a sample of Bulgarian patients with late-onset Parkinson’s disease. Am J Alzheimers Dis Other Demen. 2014;29(7):614–619.
   PubMed Web of Science ®Google Scholar
• Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183–189.
   PubMed Web of Science ®Google Scholar
• Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci. 2006;248(1–2):151–157.
   PubMed Web of Science ®Google Scholar
• Barrero FJ, Ampuero I, Morales B, et al. Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 2005;5(2):135–141.
   PubMed Web of Science ®Google Scholar
• Dissanayaka NN, Silburn PA, O’Sullivan JD, et al. Serotonin and dopamine transporter genes do not influence depression in Parkinson’s disease. Mov Disord. 2009;24(1):111–115.
   PubMed Web of Science ®Google Scholar
• Zhang JL, Yang JF, Chan P. No association between polymorphism of serotonin transporter gene and depression in Parkinson’s disease in Chinese. Neurosci Lett. 2009;455(3):155–158.
   PubMed Web of Science ®Google Scholar
• Lesch K, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527–1531.
   PubMed Web of Science ®Google Scholar
• Mössner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson’s disease. Mol Psychiatry. 2001;6(3):350–352.
   PubMed Web of Science ®Google Scholar
• Menza M, Palermo B, DiPaola R, et al. Depression and anxiety in Parkinson’s disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol. 1999;12(2):49–52.
   PubMed Web of Science ®Google Scholar
• Burn DJ, Tiangyou W, Allcock LM, et al. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson’s disease. Parkinsonism Relat Disord. 2006;12(3):139–141.
   PubMed Web of Science ®Google Scholar
• Hua P, Liu W, Kuo SH, et al. Association of Tef polymorphism with depression in Parkinson disease. Mov Disord. 2012;27(13):1694–1697.
   PubMed Web of Science ®Google Scholar
• Soria V, Martinez-Amoros E, Escaramis G, et al. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology. 2010;35(6):1279–1289.
   PubMed Web of Science ®Google Scholar
• Hua P, Liu W, Chen D, et al. Cry1 and Tef gene polymorphisms are associated with major depressive disorder in the Chinese population. J Affect Disord. 2014;157:100–103.
   PubMed Web of Science ®Google Scholar
• Lavebratt C, Sjöholm L, Soronen P, et al. CRY2 is associated with depression. PLoS One. 2010;5(2):e9407.
   Google Scholar
• Kishi T, Yoshimura R, Kitajima T, et al. SIRT1 gene is associated with major depressive disorder in the Japanese population. J Affect Disord. 2010;126(1–2):167–173.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen J, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–392.
   PubMedGoogle Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
   PubMed Web of Science ®Google Scholar
• Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012;78(18):1434–1440.
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Westman E, Ballard C, et al. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697–707.
   PubMed Web of Science ®Google Scholar
• Marder K, Maestre G, Cote L, et al. The apolipoprotein epsilon 4 allele in Parkinson’s disease with and without dementia. Neurology. 1994;44(7):1330–1331.
   PubMed Web of Science ®Google Scholar
• Ezquerra M, Campdelacreu J, Gaig C, et al. Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease. Neurosci Lett. 2008;448(1):20–23.
   PubMed Web of Science ®Google Scholar
• Kurz MW, Dekomien G, Nilsen OB, et al. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr Psychiatry Neurol. 2009;22(3):166–170.
   PubMed Web of Science ®Google Scholar
• Ryu HG, Kwon OD. Apolipoprotein E epsilon 4 allele is not associated with age at onset or MMSE of Parkinson’s disease in a Korean study. Parkinsonism Relat Disord. 2010;16(9):615–617.
   PubMed Web of Science ®Google Scholar
• Meeus B, Verstraeten A, Crosiers D, et al. DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiol Aging. 2012;33(3):629.e5–629.e18.
   Web of Science ®Google Scholar
• Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J Neurol. 2009;256(3):493–498.
   PubMed Web of Science ®Google Scholar
• Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson’s disease and a higher risk with dementia. Mov Disord. 2006;21(1):45–49.
   PubMed Web of Science ®Google Scholar
• Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson’s disease. Mov Disord. 2012;27(4):512–518.
   PubMed Web of Science ®Google Scholar
• Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol. 2014;71(11):1405–1412.
   PubMed Web of Science ®Google Scholar
• Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72(4):587–598.
   PubMed Web of Science ®Google Scholar
• De Marchi F, Carecchio M, Cantello R, et al. Predicting cognitive decline in Parkinson’s disease: can we ask the genes? Front Neurol. 2014;5:224.
   PubMed Web of Science ®Google Scholar
• Halliday GM, Leverenz JB, Schneider JS, et al. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord. 2014;29(5):634–650.
   PubMed Web of Science ®Google Scholar
• Zarranz J, Alegre J, Gómez-Esteban J, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164–173.
   PubMed Web of Science ®Google Scholar
• Somme JH, Gomez-Esteban JC, Molano A, et al. Initial neuropsychological impairments in patients with the E46K mutation of the alpha-synuclein gene (PARK 1). J Neurol Sci. 2011;310(1–2):86–89.
   PubMed Web of Science ®Google Scholar
• Shin CW, Kim HJ, Park SS, et al. Two Parkinson’s disease patients with alpha-synuclein gene duplication and rapid cognitive decline. Mov Disord. 2010;25(7):957–959.
   PubMed Web of Science ®Google Scholar
• Ross OA, Braithwaite AT, Skipper LM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63(6):743–750.
   PubMed Web of Science ®Google Scholar
• De Marco EV, Tarantino P, Rocca FE, et al. Alpha-synuclein promoter haplotypes and dementia in Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet. 2008;147(3):403–407.
   PubMed Web of Science ®Google Scholar
• Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol. 2007;62(2):145–153.
   PubMed Web of Science ®Google Scholar
• Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson’s disease is influenced by the COMT val158met polymorphism. Mov Disord. 2004;19(8):885–891.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Hampshire A, Robbins TW, et al. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson’s disease. J Neurosci. 2007;27(18):4832–4838.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(Pt 11):2958–2969.
   PubMed Web of Science ®Google Scholar
• Nombela C, Rowe J, Winder-Rhodes S, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain. 2014;137:2743–458.
   PubMed Web of Science ®Google Scholar
• Hoogland J, de Bie RM, Williams-Gray CH, et al. Catechol-O-methyltransferase val158met and cognitive function in Parkinson’s disease. Mov Disord. 2010;25(15):2550–2554.
   PubMed Web of Science ®Google Scholar
• Setó-Salvia N, Clarimón J, Pagonabarraga J, et al. Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol. 2011;68(3):359–364.
   PubMedGoogle Scholar
• Sidransky E, Nalls M, Aasly J, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;631(17):1651–1661.
   Web of Science ®Google Scholar
• Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain. 2009;132(Pt 7):1783–1794.
   PubMed Web of Science ®Google Scholar
• Brockmann K, Srulijes K, Hauser A, et al. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011;77(3):276–280.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013;70(7):852–858.
   PubMed Web of Science ®Google Scholar
• Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain. 2013;136(Pt 2):392–399.
   PubMed Web of Science ®Google Scholar
• Brockmann K, Srulijes K, Pflederer S, et al. GBA-associated Parkinson’s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord. 2015;30(3):407–411.
   PubMed Web of Science ®Google Scholar
• Foltynie T, Lewis SG, Goldberg TE, et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease. J Neurol. 2005;252(7):833–838.
   PubMed Web of Science ®Google Scholar
• Guerini FR, Beghi E, Riboldazzi G, et al. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson’s disease. Eur J Neurol. 2009;16(11):1240–1245.
   PubMed Web of Science ®Google Scholar
• Bialecka M, Kurzawski M, Roszmann A, et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson’s disease. Neurosci Lett. 2014;561:86–90.
   PubMed Web of Science ®Google Scholar
• Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17–23.
   PubMed Web of Science ®Google Scholar
• Laumet G, Chouraki V, Grenier-Boley B, et al. Systematic analysis of candidate genes for Alzheimer’s disease in a French, genome-wide association study. J Alzheimers Dis. 2010;20(4):1181–1188.
   PubMed Web of Science ®Google Scholar
• Gatt AP, Jones EL, Francis PT, et al. Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson’s disease dementia but not dementia with Lewy bodies. Neurosci Lett. 2013;557(Pt B):177–180.
   PubMed Web of Science ®Google Scholar
• Stocchi F. Neuroprotection in Parkinson’s disease: a difficult challenge. Lancet Neurol. 2015;14(8):780–781.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson’s disease? Ann Neurol. 2008;64(Suppl 2):S101–S110.
   PubMed Web of Science ®Google Scholar
• Yacoubian TA, Standaert DG. Targets for neuroprotection in Parkinson’s disease. Biochim Biophys Acta. 2009;1792(7):676–687.
   PubMed Web of Science ®Google Scholar
• Racette B, Willis A. Time to change the blind men and the elephant approach to Parkinson disease? Neurology. 2015;85(2):190–196.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Fasano A, Morgante F. The six gaps in the search of neuroprotection for Parkinson’s disease. Expert Rev Neurother. 2012;12(2):111–113.
   PubMed Web of Science ®Google Scholar
• Lang AE, Melamed E, Poewe W, et al. Trial designs used to study neuroprotective therapy in Parkinson’s disease. Mov Disord. 2013;28(1):86–95.
   PubMed Web of Science ®Google Scholar
• Schapira A, Olanow C. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA. 2004 Jan 21;291(3):358–364.
   PubMed Web of Science ®Google Scholar
• Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Transl Med. 2012;4(141):141ra90.
   PubMed Web of Science ®Google Scholar
• Pacanowski M, Huang SM. Precision medicine. Clin Pharmacol Ther. 2016;99(2):124–129.
   PubMed Web of Science ®Google Scholar
• Hamburg M, Collins F. The path to personalized medicine. N Engl J Med. 2010;363(4):301–304.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Weitzel KW. Advancing pharmacogenomics as a component of precision medicine: how, where, and who? Clin Pharmacol Ther. 2016;99(2):154–156.
   PubMed Web of Science ®Google Scholar